31.10.2014 Views

Annual Report 2008-09 - Austin Health

Annual Report 2008-09 - Austin Health

Annual Report 2008-09 - Austin Health

SHOW MORE
SHOW LESS

You also want an ePaper? Increase the reach of your titles

YUMPU automatically turns print PDFs into web optimized ePapers that Google loves.

LUDWIG INSTITUTE FOR CANCER<br />

RESEARCH AT AUSTIN HEALTH<br />

Prof Andrew Scott, Director of the<br />

Ludwig Institute for Cancer Research<br />

(LICR) at <strong>Austin</strong> Hospital led a team<br />

responsible for the development of a<br />

new paradigm in targeting cancer cells,<br />

the monoclonal antibody (mAb) 806.<br />

Preclinical investigations and a phase<br />

one, first-in-man trial at <strong>Austin</strong> Hospital<br />

in 2007, determined that mAb806 binds<br />

to a previously unreported epitope of<br />

the Epidermal Growth Factor Receptor<br />

(EGFR) that is only exposed in overexpressed,<br />

mutated or amplified EGFR.<br />

Over-expression of EGFR occurs in<br />

more than 50 per cent of some types of<br />

cancers. Current therapies that target<br />

EGFR cause side-effects by targeting<br />

EGFR both when it is over-expressed on<br />

cancer cells and when it is present in<br />

usual amounts on normal cells.<br />

Unlike these reagents, mAb806 has been<br />

shown in pre-clinical testing to have no<br />

cross-reactivity with normal tissue, and<br />

is the first tumour-specific antibody<br />

directed towards a cancer-related<br />

growth factor receptor.<br />

In November one of the LICR<br />

spin-off companies, Life Science<br />

Pharmaceuticals, licensed mAb806 to<br />

pharmaceutical company Abbott. LICR<br />

at <strong>Austin</strong> <strong>Health</strong> continues to be actively<br />

involved with Abbott in the ongoing<br />

clinical development of this exciting<br />

cancer therapy candidate.<br />

NHMRC EXCELLENCE AWARDS <strong>2008</strong><br />

Reinforcing <strong>Austin</strong> <strong>Health</strong>’s national<br />

importance as a research precinct,<br />

two of its researchers were recognised<br />

with prestigious NHMRC Excellence<br />

Awards, only given to the seven<br />

highest-ranking grant and fellowship<br />

recipients in Australia.<br />

Neurologist Prof Graeme Jackson,<br />

Director and founder of the Brain<br />

Research Institute was recognised<br />

for his work defining the causes of<br />

epilepsy and classifying the brain’s<br />

developmental abnormalities using<br />

magnetic resonance imaging.<br />

Dr Sofianos Andrikopoulos, head of<br />

the Islet Biology Research Group at The<br />

University of Melbourne Department<br />

of Medicine at <strong>Austin</strong> <strong>Health</strong>, was<br />

recognised for research that suggested<br />

that a common class of drugs used to<br />

treat type 2 diabetes, sulfonylureas,<br />

actually accelerate the disease.<br />

AUSTIN LIFESCIENCES<br />

RESEARCH WEEK<br />

Researchers from <strong>Austin</strong> <strong>Health</strong> and its<br />

associated institutions and universities<br />

participated in the annual Research<br />

Week celebrations in October. The <strong>Austin</strong><br />

LifeSciences Symposium and plenary<br />

session were popular events, and 153<br />

researchers displayed their work in the<br />

annual poster competition.<br />

Numerous awards were given for<br />

excellence in various fields of research,<br />

including allied health, cancer, stroke,<br />

nursing, parent/infant, clinical and<br />

general research. The <strong>2008</strong> Distinguished<br />

Scientist Award was presented to<br />

endocrinologist and internationallyrecognised<br />

expert on osteoporosis<br />

Prof Ego Seeman for his contribution to<br />

the <strong>Austin</strong> research community over his<br />

career at <strong>Austin</strong> <strong>Health</strong>.<br />

Rising talent Dr Cherie Chiang won both<br />

awards open to young researchers – the<br />

<strong>Austin</strong> Lifesciences Award for Basic<br />

Research and the Young Investigator<br />

Award, for her abstract Mineralisation<br />

and Bone Resorption are Regulated by<br />

the Androgen Receptor in Male Mice.<br />

NATIONAL HEALTH AND<br />

MEDICAL RESEARCH COUNCIL<br />

GRANT WINNERS 20<strong>09</strong><br />

Prof L Burrell: Vasopressin and<br />

heart failure, $551,250<br />

Prof E Seeman, Dr R Zebaze and<br />

team: Cortical porosity to bone<br />

fragility, $596,250<br />

Prof J Proietto: Understanding how<br />

obesity and abnormal lipids are<br />

linked, $320,100<br />

Prof G Jerums, Assoc Prof R<br />

MacIsaac and team: eGFR in<br />

indigenous Australians, $926,200<br />

Prof J Zajac, Dr R Davey and team:<br />

Male hormone receptors in boneforming<br />

cells, $451,625<br />

Dr S Andrikopoulos, Dr B Fam and<br />

team: The role of a liver enzyme in<br />

controlling body weight, $475,125<br />

Assoc Prof I Davis, Prof J Cebon,<br />

Assoc Prof W Chen and team:<br />

Immune targeting of melanoma<br />

stem cells, $506,250<br />

Prof A Scott, Dr P Ramsland and<br />

team: Using the immune system to<br />

treat cancers, $543,500<br />

Prof D Power: Waste control in<br />

kidney disease, $438,000<br />

Dr D Christiansen, Dr P Ramsland,<br />

Dr H Vaughan, Prof M Sandrin and<br />

team: The role of carbohydrates in<br />

transplantation, $541,500<br />

Prof R Bellomo and team:<br />

Erythropoietin in Traumatic Brain<br />

Injury (EPO-TBI), $1,848,475<br />

<strong>Austin</strong> <strong>Health</strong> : <strong>2008</strong>-<strong>09</strong> ANNUAL REPORT<br />

27

Hooray! Your file is uploaded and ready to be published.

Saved successfully!

Ooh no, something went wrong!